Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 57 (9), 1842-9

Circulating Peroxiredoxin 4 and Type 2 Diabetes Risk: The Prevention of Renal and Vascular Endstage Disease (PREVEND) Study


Circulating Peroxiredoxin 4 and Type 2 Diabetes Risk: The Prevention of Renal and Vascular Endstage Disease (PREVEND) Study

Ali Abbasi et al. Diabetologia.


Aims/hypothesis: Oxidative stress plays a key role in the development of type 2 diabetes mellitus. We previously showed that the circulating antioxidant peroxiredoxin 4 (Prx4) is associated with cardiometabolic risk factors. We aimed to evaluate the association of Prx4 with type 2 diabetes risk in the general population.

Methods: We analysed data on 7,972 individuals from the Prevention of Renal and Vascular End-stage Disease (PREVEND) study (49% men, aged 28-75 years) with no diabetes at baseline. Logistic regression models adjusted for age, sex, smoking, waist circumference, hypertension and family history of diabetes were used to estimate the ORs for type 2 diabetes.

Results: During a median follow up of 7.7 years, 496 individuals (288 men; 58%) developed type 2 diabetes. The median (Q1-Q3) Prx4 level was 0.84 (0.53-1.40) U/l in individuals who developed type 2 diabetes and 0.68 (0.43-1.08) U/l in individuals who did not develop type 2 diabetes. For every doubling of Prx4 levels, the adjusted OR (95% CI) for type 2 diabetes was 1.16 (1.05-1.29) in the whole population; by sex, it was 1.31 (1.14-1.50) for men and 1.03 (0.87-1.21) for women. Further adjustment for other clinical measures did not materially change the results. The addition of Prx4 to a validated diabetes risk score significantly improved the prediction of type 2 diabetes in men (p = 0.002 for reclassification improvement).

Conclusions/interpretation: Our findings suggest that elevated serum Prx4 levels are associated with a higher risk of incident type 2 diabetes. For men, taking Prx4 into consideration can improve type 2 diabetes prediction over a validated diabetes risk score; in contrast, there is no improvement in risk prediction for women.


Fig. 1
Fig. 1
Nonlinear relationship between Prx4 and new-onset type 2 diabetes mellitus. Data are shown for 7,952 participants without diabetes at baseline. A fractional polynomials model was fitted to examine the linearity and determine the functional form of Prx4. The optimal transformation of Prx4 was one in which the term Prx4−0.5 was incorporated; OR for diabetes = exp(β × (x-median)−0.5), where β is the regression coefficient for transformed Prx4 (x). The plotted ORs (solid line) and 95% CI (shaded area) were calculated for different values of Prx4 compared with the median Prx4 value, which was used as the reference. Prx, peroxiredoxin; T2DM, type 2 diabetes mellitus

Similar articles

See all similar articles

Cited by 5 articles


    1. Seshasai SR, Kaptoge S, Thompson A, et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med. 2011;364:829–841. doi: 10.1056/NEJMoa1008862. - DOI - PMC - PubMed
    1. Danaei G, Finucane MM, Lu Y, et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet. 2011;378:31–40. doi: 10.1016/S0140-6736(11)60679-X. - DOI - PubMed
    1. Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J Clin Invest. 2005;115:1111–1119. doi: 10.1172/JCI200525102. - DOI - PMC - PubMed
    1. Giustarini D, Dalle-Donne I, Tsikas D, Rossi R. Oxidative stress and human diseases: origin, link, measurement, mechanisms, and biomarkers. Crit Rev Clin Lab Sci. 2009;46:241–281. doi: 10.3109/10408360903142326. - DOI - PubMed
    1. Matsushita K, Williams EK, Mongraw-Chaffin ML, et al. The association of plasma lactate with incident cardiovascular outcomes: the ARIC study. Am J Epidemiol. 2012;178:401–409. doi: 10.1093/aje/kwt002. - DOI - PMC - PubMed

Publication types